U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H20N2O4S
Molecular Weight 372.438
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LERIGLITAZONE

SMILES

CC(O)C1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1

InChI

InChIKey=OXVFDZYQLGRLCD-UHFFFAOYSA-N
InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)

HIDE SMILES / InChI

Molecular Formula C19H20N2O4S
Molecular Weight 372.438
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Hydroxypioglitazone (M-IV) is an active metabolite of the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. Experiments in vitro have shown that hydroxypioglitazone was more efficient than the parent drug in stimulating lipid synthesis.

Approval Year

PubMed

PubMed

TitleDatePubMed
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
1996 Dec 20
Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study.
2013 Jul 1
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.
2014 Oct 15
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:38:10 UTC 2023
Edited
by admin
on Fri Dec 15 16:38:10 UTC 2023
Record UNII
K824X25AYA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LERIGLITAZONE
INN   USAN  
Official Name English
leriglitazone [INN]
Common Name English
LERIGLITAZONE [USAN]
Common Name English
HYDROXYPIOGLITAZONE
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-(1-HYDROXYETHYL)-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-
Systematic Name English
MIN-102
Code English
ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 552716
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
FDA ORPHAN DRUG 700919
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
Code System Code Type Description
EU-Orphan Drug
EU/3/16/1770(POSITIVE)
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY Treatment of adrenoleukodystrophy 18/11/2016 Positive
CAS
146062-44-4
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
EVMPD
SUB196367
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
PUBCHEM
4147757
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
INN
10868
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
NCI_THESAURUS
C170108
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID30399914
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
USAN
GH-65
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
SMS_ID
100000182339
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
DRUG BANK
DB15021
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
FDA UNII
K824X25AYA
Created by admin on Fri Dec 15 16:38:10 UTC 2023 , Edited by admin on Fri Dec 15 16:38:10 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY